<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143984</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HNCNS-2019-34</org_study_id>
    <nct_id>NCT04143984</nct_id>
  </id_info>
  <brief_title>Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase 2 Randomized Clinical Trial to Examine the Efficacy of Carbon-Ion Radiotherapy Plus Camrelizumab As Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the role of camrezlizumab in addition to carbon-ion&#xD;
      radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal carcinoma. According&#xD;
      to the plan, a total of 146 patients will be recruited and randomized into: 1) CIRT alone&#xD;
      group (control group); 2) CIRT plus camrelizumab group (experimental group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment for locally recurrent nasopharyngeal carcinoma (LR-NPC) is challenging. Carbon-ion&#xD;
      radiotherapy appeared to be an effective treatment for this group of patients, and has&#xD;
      substantially improved the 2-year overall survival (OS) to approximately 85%, compared to&#xD;
      photon-based intensity-modulated radiotherapy. However, a group of the patients may still&#xD;
      develop disease progression after CIRT, and the 2-year progression-free survival (PFS) was&#xD;
      approximately 45%-50%. Camrelizumab, a programmed cell death 1 (PD-1) inhibitor, has been&#xD;
      demonstrated that it is effective in the recurrent/metastatic nasopharyngeal carcinoma;&#xD;
      however, the role of camrelizumab in concurrence with radiotherapy, especially CIRT, for&#xD;
      LR-NPC is not clear. The purpose of this phase 2 clinical trial is to compare the efficacy of&#xD;
      CIRT plus camrelizumab and CIRT alone in the treatment of LR-NPC. Eligible participants will&#xD;
      be randomized (1:1) to 1) CIRT alone group (control group); 2) CIRT plus camrelizumab group&#xD;
      (experimental group). The primary endpoint is progression-free survival. Secondary endpoints&#xD;
      include overall survival (OS), local progression-free survival (LPFS), regional&#xD;
      progression-free survival (RPFS), and distant metastasis-free survival (DMFS) and toxicities.&#xD;
      All efficacy analyses are conducted in the intention-to-treat population, and the safety&#xD;
      population include only patients who receive their randomly assigned treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>Duration from randomization to documented disease recurrence or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
    <description>Duration from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>Duration from randomization to documented local recurrence or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>Duration from randomization to documented regional recurrence or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>Duration from randomization to documented distant metastasis or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>2-year</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive induction chemotherapy followed by carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive induction chemotherapy followed by carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy</intervention_name>
    <description>Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.</description>
    <arm_group_label>Arm-C</arm_group_label>
    <arm_group_label>Arm-CC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon-ion radiotherapy</intervention_name>
    <description>Accelerated carbon-ion beam with pencil beam scanning technique.</description>
    <arm_group_label>Arm-C</arm_group_label>
    <arm_group_label>Arm-CC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>An anti-PD-1 antibody.</description>
    <arm_group_label>Arm-CC</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed a definitive course of intensity-modulated photon radiation therapy (IMRT)&#xD;
             to a total dose of ≥ 66 Gy&#xD;
&#xD;
          -  Recurrence at nasopharynx diagnosed more than 6 months after the initial course of&#xD;
             IMRT&#xD;
&#xD;
          -  Patients with neck lymphadenopathy should receive neck dissection before randomization&#xD;
&#xD;
          -  With measurable lesion on contrast MR scan&#xD;
&#xD;
          -  Age ≥ 18 and &lt; 70 years of age&#xD;
&#xD;
          -  ECOG score: 0-1&#xD;
&#xD;
          -  Leucocyte count ≥ 4000/µL, neutrocyte count ≥ 2000/µL, platelet count ≥ 100000/µL,&#xD;
             hemoglobin ≥ 90g/L&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) &lt; 1.5×upper limit&#xD;
             of normal (ULN), alkaline phosphatase &lt; 2.5×ULN, bilirubin ≤ ULN, serum creatinine ≤&#xD;
             ULN, creatinine clearance ≥ 60ml/min&#xD;
&#xD;
          -  Willing to accept adequate contraception&#xD;
&#xD;
          -  Ability to understand the nature of the clinical trial and sign the written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastasis&#xD;
&#xD;
          -  Previously received radioactive particle implantation&#xD;
&#xD;
          -  Prior malignancy within 5 years before randomization, except for adequately treated&#xD;
             basal cell or squamous cell skin cancer, in-situ cervical cancer&#xD;
&#xD;
          -  Patients who received local (such as surgery and cryotherapy) or systemic treatment,&#xD;
             except for induction chemotherapy after diagnosis of recurrence&#xD;
&#xD;
          -  With uncontrolled active infection&#xD;
&#xD;
          -  With pneumonia&#xD;
&#xD;
          -  With autoimmune disease&#xD;
&#xD;
          -  With a known history of testing positive for human immunodeficiency virus (HIV) or&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Hepatitis B virus (HBV) DNA ≥ 500IU/mL for patients with positive HBV surface antigen,&#xD;
             positive hepatitis C virus RNA for patients with positive HCV antigen&#xD;
&#xD;
          -  Previously treated by immune checkpoint inhibitors&#xD;
&#xD;
          -  Medical conditions requiring treatment of antibiotics and/or corticosteroid&#xD;
&#xD;
          -  Treated with ≥ 5 days antibiotics one month before start of immunotherapy&#xD;
&#xD;
          -  With known allergy to any of the study drugs&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any severe intercurrent disease that may interfere with the current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiade J Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiyi Hu, MD, PhD</last_name>
    <phone>+8602138296666</phone>
    <phone_ext>53513</phone_ext>
    <email>jiyi.hu@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Kong, MD</last_name>
    <phone>+8602138296666</phone>
    <phone_ext>53516</phone_ext>
    <email>lin.kong@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiyi Hu, MD, PhD</last_name>
      <phone>+8602138296666</phone>
      <phone_ext>53513</phone_ext>
      <email>jiyi.hu@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lin Kong, MD</last_name>
      <phone>+8602138296666</phone>
      <phone_ext>53516</phone_ext>
      <email>lin.kong@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jiade J Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Kong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiyi Hu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weixu Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Gao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xianxin Qiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingting Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Jiade J. Lu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data on participants' clinical features, treatment modalities, survivals and toxicity profile will be shared upon reasonable request. Detailed study protocol should be emailed along with the request of the data. We may carefully review the study protocol, and data will only be shared with well-designed studies.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 3 years after publication of the study.</ipd_time_frame>
    <ipd_access_criteria>Data mentioned in the plan description and relevant supporting files will be shared with radiation oncologist who are interested in conducting pooled analysis comparing carbon-ion radiotherapy with other treatment modalities (such as other radiation technique and systemic therapy) for patients with recurrent nasopharyngeal carcinoma. The IPD will only be shared after the study protocol is reviewed and approved by the principle investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

